Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.
HER2-low
complete histologic response
prognosis
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 May 2022
19 May 2022
Historique:
received:
25
03
2022
revised:
10
05
2022
accepted:
13
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC. We retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS). 437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%, In our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation.
Identifiants
pubmed: 35626113
pii: cancers14102509
doi: 10.3390/cancers14102509
pmc: PMC9139240
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Breast Cancer Res Treat. 2021 Nov;190(1):155-163
pubmed: 34409551
BMC Cancer. 2020 Dec 7;20(1):1206
pubmed: 33287745
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Rev Med Liege. 2010 Mar;65(3):120-6
pubmed: 20411815
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Sci Rep. 2020 Jan 14;10(1):225
pubmed: 31937819
Semin Cancer Biol. 2021 Jul;72:123-135
pubmed: 32112814
PLoS One. 2016 Jul 29;11(7):e0153459
pubmed: 27472762
Oncotarget. 2018 May 29;9(41):26406-26416
pubmed: 29899867
Curr Opin Oncol. 2020 Nov;32(6):545-554
pubmed: 32925204
Onco Targets Ther. 2016 Jul 27;9:4653-60
pubmed: 27536129
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Oncogene. 2005 Jul 7;24(29):4660-71
pubmed: 15897907
J Clin Oncol. 2008 Aug 20;26(24):3913-5
pubmed: 18711176
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Ann Oncol. 2014 Aug;25(8):1570-7
pubmed: 24827135
Breast Cancer Res Treat. 2012 Apr;132(3):1049-62
pubmed: 22198468
Ann Oncol. 2015 Dec;26(12):2505-6
pubmed: 26467471
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Br J Cancer. 2014 May 13;110(10):2524-30
pubmed: 24675383
Ann Oncol. 2005 Nov;16(11):1723-39
pubmed: 15980158
Ann Oncol. 2019 Sep 1;30(9):1437-1447
pubmed: 31218365
Ann Oncol. 2013 Nov;24(11):2786-93
pubmed: 23970015
Breast Cancer Res. 2019 May 17;21(1):65
pubmed: 31101122
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Breast Cancer Res Treat. 2012 Sep;135(2):531-7
pubmed: 22864769
PLoS One. 2018 Nov 14;13(11):e0207224
pubmed: 30427884
Br J Cancer. 2007 May 21;96(10):1504-13
pubmed: 17453008
Cell. 2018 May 3;173(4):879-893.e13
pubmed: 29681456
Clin Cancer Res. 2018 Apr 15;24(8):1845-1852
pubmed: 29378733
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Oncologist. 2012;17(11):1418-25
pubmed: 22951668
Int J Biol Markers. 2014 Sep 30;29(3):e187-92
pubmed: 25041784
Int J Surg Oncol. 2012;2012:653608
pubmed: 23304480
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
J Pathol. 2014 Jan;232(2):142-50
pubmed: 24114677
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Bull Cancer. 2016 Jun;103(6 Suppl 1):S76-89
pubmed: 27494978
Breast Cancer Res Treat. 2010 Nov;124(1):133-40
pubmed: 20697801
Front Oncol. 2013 May 21;3:129
pubmed: 23734345
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Mol Oncol. 2022 Jan;16(1):69-87
pubmed: 34051058
Int J Cancer. 2019 Dec 15;145(12):3414-3424
pubmed: 31087550
Oncol Lett. 2019 Dec;18(6):6275-6283
pubmed: 31788105
Clin Transl Oncol. 2019 Jul;21(7):855-863
pubmed: 30506134
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Ann Surg Oncol. 2016 Apr;23(4):1104-10
pubmed: 26511266
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Oncologist. 2013;18(2):123-33
pubmed: 23404817